Merantix Capital's €103M AI Fund: Backing Europe's AI-Native Builders
Merantix Capital closed a €103M fund in June 2026 to back early-stage European AI startups across logistics, manufacturing, energy, healthcare, robotics, and physical AI.
European Venture Capital News & Startup Funding
Europe's venture capital market is maturing rapidly, with growing LP appetite for deep tech, defense, fintech, and sovereign AI capabilities. Our European VC coverage tracks fund formation, mega-rounds, and the policy and capital dynamics shaping the continent's startup ecosystem.
European VC Themes
- Deep tech & defense: Robotics, quantum, space, and dual-use technologies
- Sovereign AI: Foundation models, data centers, and national investment programs
- Fund formation: Pan-European funds and sector-specific vehicles
- Hub activity: London, Paris, Berlin, Stockholm, and emerging markets
Browse European venture capital articles for regional funding insight.
Related Articles (42 articles)
Oxford Quantum Circuits's £260M: Europe's Largest Quantum Round
OQC closed an oversubscribed £260M Series C in June 2026 — Europe's biggest private quantum funding round — to scale superconducting quantum computing.
Quobly's €115M Series A: France Bets on Silicon-Based Quantum
French quantum startup Quobly raised €115M Series A in June 2026 to industrialize silicon-based quantum processors compatible with existing semiconductor fabs.
Endra's $50M Series A: Automating Building Design for MEP Engineers
Stockholm AI startup Endra raised $50M Series A in June 2026 to automate design work for mechanical, electrical, and plumbing (MEP) consultants.
IMU Biosciences's $53M+: Decoding the Immune System at Scale
UK biotech IMU Biosciences extended its oversubscribed Series A past $53M in June 2026 to map and decode the human immune system for drug discovery.
Ona Therapeutics's $86.6M Series B: Barcelona's ADC Cancer Bet
Barcelona biopharma Ona Therapeutics closed an oversubscribed $86.6M Series B in June 2026 to advance first-in-class antibody-drug conjugates for resistant cancers.